Diretrizes do Rastreamento do Câncer Cervical
Palavras-chave:
colo uterino, câncer, mulheresReferências
Vale DB, Sauvaget C, Muwonge R, Thuler LC, Basu P, Zeferino LC, et al. Level of human development is associated with cervical cancer stage at diagnosis. J Obstet Gynaecol. 2019;39(1):86-90. doi: 10.1080/01443615.2018.1463976
Vale DB, Sauvaget C, Muwonge R, Ferlay J, Zeferino LC, Murillo R, et al. Disparities in time trends of cervical cancer mortality rates in Brazil Cancer Causes Control. 2016;27(7):889-96. doi: 10.1007/s10552- 016-0766-x
Ronco G, Dillner 1, Elfström KM, Tunesi S, Snijders Pl, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916) 524-32. doi: 10.1016/S0140-6736(13)62218-7
Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;(8):CD008587.
Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Divisão de Detecção Precoce e Apoio à Organização de Rede. Diretrizes brasileiras para o rastreamento do câncer do colo do útero. 2ª ed. Rio de Janeiro: Inca; 2016.
Zeferino LC, Bastos JB, Vale DB, Zanine RM, Melo YL, Primo WQ, et al. Guidelines for HPV-DNA testing for cervical cancer screening in Brazil. Rev Bras Ginecol Obstet. 2018;40(6):360-8. doi: 10.1055/s- 0038-1657754
Australian Institute of Health and Welfare. National Cervical Screening Program: guidelines for the management of screen- detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding [Internet]. 2021 [cited 2021 Mar 24]. Available from: https://wiki.cancer.org.au/australia/ Guidelines:Cervical cancer/Screening
Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2020;24(2):132-43. doi: 10.1097/LGT.0000000000000529
Silver MI, Andrews J, Cooper CK, Gage JC, Gold MA, Khan MJ, et al. Risk of cervical intraepithelial neoplasia 2 or worse by cytology, human papillomavirus 16/18, and colposcopy impression: a systematic review and meta-analysis. Obstet Gynecol. 2018;132(3):725-35. doi: 10.1097/AOG.0000000000002812
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. I Low Genit Tract Dis. 2020;24(2):102-31. doi: 10.1097/ LGT0000000000000525
Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020;123(4):510-7. doi: 10.1038/s41416-020-0920-9
Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an 12. observational cohort study. Ann Intern Med. 2018,168(1):20-9. doi: 10.7326/M17-1609
ter Haar-van Eck SA, Rischen-Vos J, Chadha-Ajwani S, Huikeshoven FJ. The incidence of cervical intraepithelial neoplasia among women with renal transplant in relation to cyclosporine. Br J Obstet Gynaecol. 1995;102(1):58-61. doi: 10.1111/j.1471-0528.1995.tb 09027.x.
